Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 97,390 Shares of Stock

Key Points

• Kiniksa Pharmaceuticals CEO Sanj Patel sold 97,390 shares at an average price of $38.83, totaling approximately $3.78 million, resulting in a 46.56% decrease in his position.
• The company's recent earnings report showed an EPS of $0.23, surpassing expectations, with a net revenue of $156.8 million for the quarter.
• Analysts have mixed ratings on Kiniksa Pharmaceuticals, with price targets ranging from $44.00 to $60.00, reflecting a general optimism around the stock despite a recent downgrade from "strong-buy" to "buy" by some firms.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 97,390 shares of the firm's stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the completion of the sale, the chief executive officer owned 111,794 shares in the company, valued at $4,340,961.02. This represents a 46.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kiniksa Pharmaceuticals International Trading Up 0.1%

KNSA stock traded up $0.05 on Wednesday, hitting $38.90. The company had a trading volume of 422,040 shares, compared to its average volume of 631,092. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $39.79. The stock's 50-day simple moving average is $36.10 and its 200 day simple moving average is $30.02. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of 972.74 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on KNSA shares. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an "outperform" rating in a research report on Monday, October 13th. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a "buy" rating and a $60.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of "Moderate Buy" and a consensus target price of $46.86.

Institutional Trading of Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently bought and sold shares of the stock. USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after acquiring an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $31,000. GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 582.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company's stock valued at $53,000 after acquiring an additional 1,159 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.